You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 19, 2025

CLINICAL TRIALS PROFILE FOR LORTAB


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Lortab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00174538 ↗ Codeine in Sickle Cell Disease Completed PriCara, Unit of Ortho-McNeil, Inc. Phase 1/Phase 2 2005-03-01 The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.
NCT00385684 ↗ Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed VA Office of Research and Development Phase 4 2007-10-01 The purpose of this study was to determine whether a low dose an opiate pain medication is effective for the treatment of discomfort in patients with advanced dementia. The study medication was also known as Lortab and contained both a narcotic pain medication and acetaminophen (the same pain medication as contained in Tylenol). This study was an eight-week long clinical trial for discomfort among veterans with advanced dementia who were admitted to a Nursing Home Care Unit (NHCU) at the Tuscaloosa VA Medical Center.
NCT00574015 ↗ The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache Completed Albany Medical College Phase 4 2007-12-01 This study will compare the degree of pain control provided by two techniques for persons with toothache in an emergency department. The two techniques include; - standard oral narcotic pain medication - numbing the tooth with local anesthetic by needle injection
NCT00583453 ↗ Celecoxib as a Post-tonsillectomy Pain Medication Completed Pfizer Phase 2 2007-10-01 The hypothesis is that celecoxib effectively reduces pain after a tonsillectomy and reduces post-operative narcotic use. To test this hypothesis, the study is placebo controlled (sugar pill). Half of the participants will receive a sugar pill, half will not. All participants will receive the standard post-operative pain medications. We ask participants to log the amount of medications they use daily, and the amount of pain they have each day. It is hoped that celecoxib will reduce the amount of post-operative pain medication needed.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lortab

Condition Name

Condition Name for Lortab
Intervention Trials
Pain, Postoperative 4
Pain 2
Skin Laxity 1
Adverse Reaction to Drug 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lortab
Intervention Trials
Pain, Postoperative 4
Fractures, Bone 2
Tonsillitis 2
Mucositis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lortab

Trials by Country

Trials by Country for Lortab
Location Trials
United States 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lortab
Location Trials
Tennessee 3
Texas 2
New York 2
California 1
Georgia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lortab

Clinical Trial Phase

Clinical Trial Phase for Lortab
Clinical Trial Phase Trials
Phase 4 8
Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lortab
Clinical Trial Phase Trials
Completed 9
Terminated 3
Enrolling by invitation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lortab

Sponsor Name

Sponsor Name for Lortab
Sponsor Trials
Baylor College of Medicine 2
Le Bonheur Children's Hospital 1
Texas Children's Hospital 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lortab
Sponsor Trials
Other 15
Industry 3
NIH 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Hydrocodone-Based Drugs like Lortab

Introduction

Hydrocodone, a key component of drugs like Lortab, is a widely used opioid for managing moderate to severe pain. This article delves into the clinical trials, market analysis, and future projections for hydrocodone-based medications.

Clinical Trials Overview

Efficacy and Safety

Clinical trials have consistently shown that hydrocodone is effective in alleviating pain. A randomized clinical trial comparing oral combination analgesics, including those containing hydrocodone, demonstrated significant pain relief in patients with moderate to severe pain. The trial involved 400 patients and used an intention-to-treat analysis, showing a notable reduction in pain scores over a 2-hour period[1].

Extended-release (ER) formulations of hydrocodone have also been studied extensively. These studies, including several randomized controlled trials (RCTs) and an open-label study, have shown that ER hydrocodone is significantly more effective than placebo in alleviating chronic low back pain. These trials involved over 1,200 patients and demonstrated the efficacy and safety of ER hydrocodone over 12-week and 22-week periods[4].

Safety Considerations

While hydrocodone is effective, it comes with significant safety concerns. The risk of misuse, abuse, addiction, and diversion is high, leading to the rescheduling of hydrocodone combination products from CIII to CII by the Drug Enforcement Agency in 2014. Clinical studies have highlighted serious adverse reactions, including respiratory depression, CNS depressant effects, and potential for overdose[3].

Market Analysis

Market Size and Growth

The hydrocodone market is anticipated to experience lucrative growth between 2025 and 2037. This growth is driven by the increasing application of hydrocodone in pain relief, cough treatment, and other medical conditions. The global opioids market, which includes hydrocodone, was valued at $4.4 billion in 2020 and is projected to reach $6.1 billion by 2030, growing at a CAGR of 3.2% from 2021 to 2030[5].

Regional Market Trends

North America is expected to maintain its dominance in the opioids market, including hydrocodone, due to the rising cases of arthritis and other pain-related conditions. The region's market is also bolstered by the liberty to research with narcotics for medicinal use. Europe is also anticipated to account for a significant share, driven by advancements in the healthcare sector and increasing investment in medical research[2].

Application Segments

The hydrocodone market is segmented by application, with pain relief being the most significant segment. Hydrocodone is prescribed for moderate to severe pain, depending on the drug combination, which is expected to boost the segment's growth. Other applications include cough treatment and various other medical uses[2].

Market Projections

Future Growth Drivers

The growth of the hydrocodone market is expected to be driven by several factors:

  • Increasing Prevalence of Pain-Related Conditions: The rising prevalence of cancer, arthritis, and other chronic pain conditions will continue to drive the demand for hydrocodone-based drugs.
  • Advancements in Healthcare: Improvements in healthcare infrastructure and increasing investment in medical research will further propel the market growth.
  • R&D Activities: Ongoing research and development activities aimed at creating abuse-deterrent formulations will play a crucial role in the market's future[2][5].

Challenges

Despite the growth potential, the hydrocodone market faces several challenges:

  • Abuse and Misuse: The high risk of misuse, abuse, and addiction associated with hydrocodone remains a significant concern. Regulatory measures, such as the Risk Evaluation and Mitigation Strategy (REMS) for extended-release opioids, are in place to mitigate these risks[3][4].
  • Regulatory Scrutiny: Hydrocodone products are subject to strict regulatory oversight, which can impact market dynamics.

Key Takeaways

  • Clinical Efficacy: Hydrocodone has been shown to be effective in clinical trials for managing moderate to severe pain.
  • Safety Concerns: Despite its efficacy, hydrocodone poses significant risks of misuse, abuse, and addiction.
  • Market Growth: The hydrocodone market is expected to grow significantly driven by increasing demand for pain relief and advancements in healthcare.
  • Regional Trends: North America and Europe are anticipated to be key regions driving the market growth.
  • Future Drivers: Increasing prevalence of pain-related conditions and R&D activities will drive future growth.

FAQs

What are the primary applications of hydrocodone?

Hydrocodone is primarily used for pain relief, particularly for moderate to severe pain, and also in cough treatment and other medical conditions.

What are the safety concerns associated with hydrocodone?

Hydrocodone is associated with serious safety concerns including misuse, abuse, addiction, respiratory depression, and CNS depressant effects.

How is the hydrocodone market expected to grow in the future?

The hydrocodone market is anticipated to witness lucrative growth between 2025 and 2037, driven by increasing demand for pain relief and advancements in healthcare.

Which regions are expected to dominate the hydrocodone market?

North America and Europe are expected to be the dominant regions in the hydrocodone market, driven by rising cases of pain-related conditions and advancements in healthcare.

What regulatory measures are in place to mitigate the risks associated with hydrocodone?

Regulatory measures such as the Risk Evaluation and Mitigation Strategy (REMS) for extended-release opioids are in place to mitigate the risks of misuse, abuse, and addiction associated with hydrocodone.

Sources

  1. Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on ... - JAMA Network
  2. Hydrocodone Market Size & Share, Growth Report 2037 - Research Nester
  3. Hydrocodone Bitartrate Extended-release Capsules (ZOHYDRO ER ... - PBM VA
  4. Preclinical and Clinical Pharmacology of Hydrocodone for Chronic ... - Frontiers in Pharmacology
  5. Opioids Market Size, Share, Demand & Growth Report, 2030 - Allied Market Research

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.